Bioatla LLC, of San Diego, and Telephus Medical LLC, also of San Diego, which develops vaccine products to prevent periprosthetic joint infections, said Bioatla completed a protein engineering phase of Telephus’ compound, TPH 101, which is focused on the development of neutralizing antibodies targeting a key bacterial enzyme that drives the formation of antibiotic-resistant biofilm infections on implanted medical devices.